NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Nektar Therapeutics NKTR
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$55.2M
▼ 43.9% vs FY2024
EPS · FY25
$-9.73
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-217.9%
Net margin · FY25
-297.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 55.2M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 297 cents on every revenue dollar this year.
Per share
USD -9.73
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-217.9%
Return on equity, FY2025
ROE
Operating margin-253.7%
Net margin-297.1%
Return on assets-56.2%
Each USD of equity lost 218 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 0.00
Share of profit-0.0%
Consecutive raises—
Growth
−18.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−15.7%
−18.4%
−13.3%
−6.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years+10.3%
Change, 10 years+64.3%
The share count grew 10% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 280.4M
total assets, end of FY2025
Total assetsUSD 280.4M
EquityUSD 89.8M
CashUSD 15.1M
Current ratio4.97×
Equity funds 32% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.2
0.1
1.2
0.3
0.2
0.2
0.2
0.1
0.1
0.1
0.2
0.1
Operating income $B
−0.1
−0.1
−0.3
−0.4
−0.4
−0.4
−0.4
0.7
−0.1
−0.1
−0.0
−0.0
−0.1
−0.1
−0.1
−0.0
−0.1
EBITDA $B
·
−0.1
−0.3
−0.4
−0.4
−0.4
−0.4
0.7
−0.0
−0.1
−0.0
−0.0
−0.1
−0.1
·
·
·
Income tax $B
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
Net income $B
−0.2
−0.1
−0.3
−0.4
−0.5
−0.4
−0.4
0.7
−0.1
−0.2
−0.1
−0.1
−0.2
−0.2
−0.1
−0.0
−0.1
EPS, diluted $
−9.73
−8.68
−1.45
−1.97
−2.86
−2.49
−2.52
3.78
−0.62
−1.10
−0.61
−0.42
−1.40
−1.50
−1.19
−0.40
−1.11
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−217.9
−124.1
−110.9
−70.4
−59.6
−35.8
−28.2
75.5
−109.9
−324.7
−379.7
·
·
−140.4
−92.9
−39.3
−100.1
Shares out B
0.02
0.01
0.19
0.19
0.19
0.18
0.18
0.17
0.16
0.15
0.14
0.13
0.12
0.12
0.11
0.09
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed